BillionToOne Is Solving One of Biotech’s Hardest Problems
Y Combinator sits down with BillionToOne, a biotech startup that transformed from PhD students with $300k to a $4B company. They developed a revolutionary prenatal genetic test, now used by 1 in 11 American babies, by solving the 'needle in a...
Video Snippets
BillionToOne Is Solving One of Biotech’s Hardest Problems
Y Combinator sits down with BillionToOne, a biotech startup that transformed from PhD students with $300k to a $4B company. They developed a revolutionary prenatal genetic test, now used by 1 in 11 American babies, by solving the 'needle in a haystack' problem of detecting rare DNA fragments in blood. Their core technology uses synthetic DNA to eliminate noise during amplification, making previously impossible diagnostics possible. BillionToOne is now applying this same approach to the 'holy grail' of early-stage cancer detection, aiming to catch cancer before it spreads, showcasing a strategic, phased approach to medical innovation.
https://youtube.com/watch?v=kkv5rZhrLkc